

Date: 29.07.2022



To,

BSE Limited P. J. Towers, Dalal Street Mumbai – 400001 Dear Sir,

Sub: Outcome of Board Meeting held on 29.07 2022

Ref: Hindustan Bio Sciences Limited (Scrip Code: 532041)


With reference to the subject cited, this is to inform the exchange that at the Board Meeting of M/s. Hindustan Bio Sciences Limited held on Friday, 29.07.2022 at 02:00 P M at the registered office of the company at Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad-500034, Telangana, considered and approved the following items of business.

- 1 Un-audited financial results of the company for the quarter ended 30-06-2022 placed before the board for their consideration
- 2 The Board has decided to fix date, place and time for conducting 30th Annual General Meeting of the company for the Financial Year ended 31-03-2022, along with the approval of Board Report and Notice for conducting of the Annual General Meeting on 30th September, 2022 is hereby given.
- 3 Secretarial Audit Report for the Financial Year 31-03-2022 has been discussed and the Board has noted the same.
- 4 Mr. VBSS Prasad, Practicing Company Secretary (C.P.No.4605), has been appointed as a scrutinizer for conducting E-voting in the ensuing Annual General Meeting.
- 5 Appointment of new auditor M/s. VASG & Associates in place of M/s. C Ramachandram & Company retiring auditors.
- 6 The board has reviewed the Limited Review Report for quarter ended 30.06.2022 and taken a note of the same.

The meeting concluded at 3-30 P.M

This is for your information and records.

Thanking you.



HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2, Banjara Hills, Hyderabad - 500 034, INDIA.

HINDUSTAN BIO SCIENCES LIMITED Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034 Phone No. 23555161,Fax 40205171 STATEMENT OF UN AUDITED RESULTS FOR THE QUARTER ENDED 30th JUNE,2022

No		T	Rs. In Lakhs			
	Particulars	Quarter ended 30.06.2022 31.03.2022 30.06.2021			Year ended	
1	Income from Operations	(unaudited)		30.06.2021	31.03.2022	
1	(a) Revenue from	(unaddited)	(Audited)	(unaudited)	(Audited)	
	(a) Revenue from operations (b) Other Income		in the second	100 C		
- 3	Total Revenue (m	27.14	0.27	19.42	43.65	
2	Total Revenue (1) Expenses		2000000		5.24	
		27.14	0.27	19.42	48.89	
- 1	(a) cost of material consumed				40.00	
- 1	(b) Purchases of Stock -in-trade	782000	-		e	
- 1	(c) Changes in Inventories of finished goods, Stock -	18.29		13.03	28.93	
	THIS WOLLS THE PROPERTY AND A PROPER			10000	20.00	
- 1	(d) Employee Benefit Expenses					
- 1	(e) Finance Costs	5.93	5.94	6.06	24.05	
	(1) Selling Expenses	0.03	0.22	0.07		
	(g) Depreciation and amortisation Expenses	0.33		0.23	0.50	
1	(h) Other Expenses	0.10	0.10	0.08	0.61	
1	Total Expenses(2)	4.97	32.19		0.34	
3 1	Profit/(Loss) before Exceptionals	29.65	38.45	7.49	45,91	
4 8	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2) Exceptional items	(2.51)	(38.18)	26.96	100,34	
	Profit/(Loss) before tax(3 -4)	(all of)	(30,10)	(7.54)	(51.45)	
el'i	Tax Expenses	(2.51)	120 400		Sec. The	
		12.011	(38.18)	(7.54)	(51.45)	
	a) Current Tax					
	b) Previous Taxes		-	*		
	c) Deferred Tax	-	100		0.03	
7 F	Profit /(Loss) for the period from continuing operations(5-6)		0.34		0.34	
B	Profit /(Loss) from discontinued operations	(2.51)	(38.52)	(7.54)	(51.76)	
εlτ	ax Expense of discontinued operations		-		12	
) F	Profit /Loss from Discontinued operations after tax(8-9)					
i.	Profit/(Loss) for the period(7+10)				-	
1	Tonu(coss) for the period(7+10)	(2.51)	(38.52)	(7.54)	(51.76)	
1	Other Comprehensive Income	69904567	0.000.000	201-22.00	0.78260/6375	
ľ	A (1) Items that will not be reclassified to profit or loss	S2	10.4	-		
1	(2) Income tax relating to items that will not be re-					
L	classified to profit or loss	S2	122			
E	B (1) Items that will be reclassified to profit or loss					
1	(2) Income tax relating to items that will be reclassified		100	2		
I.	to profit or loss					
311	Total Comprehensive Income for the period (11+12)	(2.51)	(38.52)	(7.54)	(51.78)	
	comprising Profit (Loss) and other comprehensive income for the per		(00.02)	1	2011-01	
	Paid up Equity Capital(Face value of Rs. 10/- each)	1,025.08	1,025.08	1,025.08	1,025.08	
	Reserves excluding Revaluation Reserves as per balance sheet of	1,020.00	1,020.00	1,020,00	1,020.00	
	previous accounting year				(946.37)	
	Earnings per equity share for continuing operations				(840.37)	
	A) Basic	10.000	10.000	10.071		
	B) Diluted	(0.02)	(0.38)	(0.07)	(0.50)	
		(0.02)	(0.38)	(0.07)	(0.50)	
	Earnings per equity share for discontinuing operations					
	A) Basic		-	-	54	
	B) Diluted	27		-	28	
	Earnings per equity share(for discontinuing & continuing operations	12/12/10/04	110-0200	C. 19		
	A) Basic	(0.02)	(0.38)	(0.07)	(0.50)	
K	B) Diluted	(0.02)	(0.38)	(0.07)	(0.50)	

Notes:

1 The Un-Audited Financial Results were taken on record by the Board of Directors in their meeting held on 29.07.2022.

2 Previous Year figures have been regrouped wherever necessary.

Place: Hyderabad Date : 29.07.2022

for Hindustan Bio Sciences Limited Austan, 0 Hyderabad J.Varun Varma Director (DIN:00515430)



C. RAMACHANDRAM & CO. CHARTERED ACCOUNTANTS

Plot No. 539, Souhiti Samriddhi, 2nd Floor, Kakatiya Hills, Madhapur, Hyderabad - 500 081. Phone : 040-42212099 E-mail : crcoca@gmail.com Web : www.crcoca.in

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEWOF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF M/S HINDUSTAN BIO SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/s HINDUSTAN BIO SCIENCES LIMITED (the "Company"), for the quarter and period ended June 30 ,2022, being prepared by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

The preparation of this statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ("IND AS 34"), prescribed under section 133 of the Companies act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India is the responsibility of the company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad Date: July 29, 2022



For C RAMACHANDRAM & CO., Chartered Accountants FR No. 002864S

N. Ale ddy N MADHUSUDAN REDDY Pariner Membership No. 241624 UDIN: 22241624ANVSYZ9257

General information about company				
Scrip code	532041			
NSE Symbol				
MSEI Symbol				
ISIN*	INE597C01013			
Name of company	HINDUSTAN BIO SCIENCES LIMITED			
Type of company				
Class of security	Equity			
Date of start of financial year	01-04-2022			
Date of end of financial year	31-03-2023			
Date of board meeting when results were approved	31-10-2022			
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	19-10-2022			
Description of presentation currency	INR			
Level of rounding used in financial results	Lakhs			
Reporting Quarter	Half yearly			
Nature of report standalone or consolidated	Standalone			
Whether results are audited or unaudited	Unaudited			
Segment Reporting	Single segment			
Description of single segment	TRADING			
Start date and time of board meeting	31-10-2022 14:00			
End date and time of board meeting	31-10-2022 15:10			
Whether cash flow statement is applicable on company	Yes			
Type of cash flow statement	Cash Flow Indirect			
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable			

	Financia	al Results – Ind-AS	
	Particulars	3 months/ 6 months ended (dd- mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
А	Date of start of reporting period	01-07-2022	01-04-2022
В	Date of end of reporting period	30-09-2022	30-09-2022
С	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Co months ended, in such case zero shall be inserted in		any has no figures for 3 months / 6
1	Income		
	Revenue from operations	0	27.14
	Other income	0	0
	Total income	0	27.14
2	Expenses		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	18.29
(c)	Changes in inventories of finished goods, work-in- progress and stock-in-trade	0	0
(d)	Employee benefit expense	6.12	12.05
(e)	Finance costs	0.06	0.09
(f)	Depreciation, depletion and amortisation expense	0.11	0.21
(f)	Other Expenses		
1	Other Expenses	1.2	6.17
2	Selling Expenses	0	0.33
10			
	Total other expenses	1.2	6.5
	Total expenses	7.49	37.14

	Financial Results	s – Ind-AS	
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
А	Date of start of reporting period	01-07-2022	01-04-2022
В	Date of end of reporting period	30-09-2022	30-09-2022
С	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated months ended, in such case zero shall be inserted in the said col		s no figures for 3 months / 6
3	Total profit before exceptional items and tax	-7.49	-10
4	Exceptional items	0	0
5	Total profit before tax	-7.49	-10
7	Tax expense		
8	Current tax	0	0
9	Deferred tax	0	0
10	Total tax expenses	0	0
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	-7.49	-10
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	-7.49	-10
22	Other comprehensive income net of taxes	0	0

	Financial Resu	ılts – Ind-AS				
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)			
А	Date of start of reporting period	01-07-2022	01-04-2022			
В	Date of end of reporting period	30-09-2022	30-09-2022			
С	Whether results are audited or unaudited	Unaudited	Unaudited			
D	Nature of report standalone or consolidated	Standalone	Standalone			
Part I	Blue color marked fields are non-mandatory. For Consolida months ended, in such case zero shall be inserted in the said		has no figures for 3 months / 6			
23	Total Comprehensive Income for the period	-7.49	-10			
24	Total profit or loss, attributable to					
	Profit or loss, attributable to owners of parent					
	Total profit or loss, attributable to non-controlling interests					
25	Total Comprehensive income for the period attributable to					
	Comprehensive income for the period attributable to owners of parent	0	0			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0			
26	Details of equity share capital					
	Paid-up equity share capital	1025.08	1025.08			
	Face value of equity share capital	10	10			
27	Details of debt securities					
28	Reserves excluding revaluation reserve					
29	Earnings per share					
i	Earnings per equity share for continuing operations					
	Basic earnings (loss) per share from continuing operations	-0.07	-0.1			
	Diluted earnings (loss) per share from continuing operations	-0.07	-0.1			
ii	Earnings per equity share for discontinued operations					
	Basic earnings (loss) per share from discontinued operations	0	0			
	Diluted earnings (loss) per share from discontinued operations	0	0			
ii	Earnings per equity share					
	Basic earnings (loss) per share from continuing and discontinued operations	-0.07	-0.1			
	Diluted earnings (loss) per share from continuing and discontinued operations	-0.07	-0.1			
30	Debt equity ratio	0	0			
31	Debt service coverage ratio	0	0			
32	Interest service coverage ratio	0	0			
33	Disclosure of notes on financial results					

Statement of Asset and Liabilities	3
Particulars	Half year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2022
Date of end of reporting period	30-09-2022
Whether results are audited or unaudited	Unaudited
Nature of report standalone or consolidated	Standalone
Assets	
1 Non-current assets	
Property, plant and equipment	3.77
Capital work-in-progress	0
Investment property	0
Goodwill	0
Other intangible assets	0
Intangible assets under development	0
Biological assets other than bearer plants	0
Investments accounted for using equity method	0
Non-current financial assets	
Non-current investments	0
Trade receivables, non-current	0
Loans, non-current	238.97
Other non-current financial assets	0
Total non-current financial assets	238.97
Deferred tax assets (net)	0.56
Other non-current assets	0
Total non-current assets	243.3
2 Current assets	
Inventories	0
Current financial asset	
Current investments	0
Trade receivables, current	38.97
Cash and cash equivalents	0.21
Bank balance other than cash and cash equivalents	0.66
Loans, current	32.81
Other current financial assets	0
Total current financial assets	72.65
Current tax assets (net)	0
Other current assets	0
Total current assets	72.65

	Statement of Asset and Liabilities					
	Particulars	Half year ended (dd-mm-yyyy)				
	Date of start of reporting period	01-04-2022				
	Date of end of reporting period	30-09-2022				
	Whether results are audited or unaudited	Unaudited				
	Nature of report standalone or consolidated	Standalone				
3 1	Non-current assets classified as held for sale	0				
4 I	Regulatory deferral account debit balances and related deferred tax Assets	0				
	Total assets	315.95				
I	Equity and liabilities					
I	Equity					
Equity attributable to owners of parent						
I	Equity share capital	1025.08				
(Other equity	-956.38				
	Total equity attributable to owners of parent	68.699999999999999				
1	Non controlling interest					
	Total equity	68.699999999999999				
I	Liabilities					
ľ	Non-current liabilities					
1	Non-current financial liabilities					
I	Borrowings, non-current	115.72				
1	Irade payables, non-current	0				
0	Other non-current financial liabilities	0				
	Total non-current financial liabilities	115.72				
I	Provisions, non-current	C				
Ι	Deferred tax liabilities (net)	C				
Ι	Deferred government grants, Non-current	C				
0	Other non-current liabilities	(
	Total non-current liabilities	115.72				
(Current liabilities					
(Current financial liabilities					
ł	Borrowings, current	128.94				
J	Frade payables, current	0.24				
(Other current financial liabilities	0				
	Total current financial liabilities	129.18				
(Other current liabilities	0				
F	Provisions, current	2.35				
(Current tax liabilities (Net)	C				
Ι	Deferred government grants, Current	C				
	Total current liabilities	131.53				
3 I	Liabilities directly associated with assets in disposal group classified as held for sale	0				
-	Regulatory deferral account credit balances and related deferred tax liability	0				
	Total liabilities	247.25				

	Particulars	3 months/ 6 month ended (dd- mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-07-2022	01-04-2022
	Date of end of reporting period	30-09-2022	30-09-2022
	Whether accounts are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
1	Segment Revenue (Income)		
	(net sale/income from each segment should be disclo	osed)	
	Total Segment Revenue		
	Less: Inter segment revenue		
	Revenue from operations		
2	Segment Result		
	Profit (+) / Loss (-) before tax and interest from each	h segment	
	Total Profit before tax		
	i. Finance cost		
	ii. Other Unallocable Expenditure net off Unallocable income		
	Profit before tax		
3	(Segment Asset - Segment Liabilities)		
	Segment Asset		
	Total Segment Asset		
	Un-allocable Assets		
	Net Segment Asset		
4	Segment Liabilities		
	Segment Liabilities		
	Total Segment Liabilities		
	Un-allocable Liabilities		
	Net Segment Liabilities		
	Disclosure of notes on segments		·

	Particulars	6 months ended (dd-mm-
		уууу)
A	Date of start of reporting period	01-04-2022
B	Date of end of reporting period	30-09-2022
С	Whether results are audited or unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone
art I	Blue color marked fields are non-mandatory.	
	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	-
	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	
	Adjustments for decrease (increase) in inventories	
	Adjustments for decrease (increase) in trade receivables, current	-25.
	Adjustments for decrease (increase) in trade receivables, non-current	
	Adjustments for decrease (increase) in other current assets	6.
	Adjustments for decrease (increase) in other non-current assets	
	Adjustments for other financial assets, non-current	
	Adjustments for other financial assets, current	19
	Adjustments for other bank balances	
	Adjustments for increase (decrease) in trade payables, current	0
	Adjustments for increase (decrease) in trade payables, non-current	
	Adjustments for increase (decrease) in other current liabilities	
	Adjustments for increase (decrease) in other non-current liabilities	
	Adjustments for depreciation and amortisation expense	0
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	
	Adjustments for provisions, current	0.
	Adjustments for provisions, non-current	
	Adjustments for other financial liabilities, current	
	Adjustments for other financial liabilities, non-current	
	Adjustments for unrealised foreign exchange losses gains	
	Adjustments for dividend income	
	Adjustments for interest income	
	Adjustments for share-based payments	
	Adjustments for fair value losses (gains)	
	Adjustments for undistributed profits of associates	
	Other adjustments for which cash effects are investing or financing cash flow	
	Other adjustments to reconcile profit (loss)	
	Other adjustments for non-cash items	
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	
	Total adjustments for reconcile profit (loss)	1.
	Net cash flows from (used in) operations	-8.
\neg	Dividends received	
	Interest paid	

Interest received	0
Income taxes paid (refund)	0
Other inflows (outflows) of cash	0
Net cash flows from (used in) operating activities	-8.59
Cash flows from used in investing activities	
Cash flows from losing control of subsidiaries or other businesses	0
Cash flows used in obtaining control of subsidiaries or other businesses	0
Other cash receipts from sales of equity or debt instruments of other entities	0
Other cash payments to acquire equity or debt instruments of other entities	0
Other cash receipts from sales of interests in joint ventures	0
Other cash payments to acquire interests in joint ventures	0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
Proceeds from sales of property, plant and equipment	0
Purchase of property, plant and equipment	0
Proceeds from sales of investment property	0
Purchase of investment property	0
Proceeds from sales of intangible assets	0
Purchase of intangible assets	0
Proceeds from sales of intangible assets under development	0
Purchase of intangible assets under development	0
Proceeds from sales of goodwill	0
Purchase of goodwill	0
Proceeds from biological assets other than bearer plants	0
Purchase of biological assets other than bearer plants	0
Proceeds from government grants	0
Proceeds from sales of other long-term assets	C
Purchase of other long-term assets	(
Cash advances and loans made to other parties	(
Cash receipts from repayment of advances and loans made to other parties	C
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	C
Dividends received	C
Interest received	0
Income taxes paid (refund)	0
Other inflows (outflows) of cash	0
Net cash flows from (used in) investing activities	0
Cash flows from used in financing activities	
Proceeds from changes in ownership interests in subsidiaries	0
Payments from changes in ownership interests in subsidiaries	0
Proceeds from issuing shares	0
Proceeds from issuing other equity instruments	(
Payments to acquire or redeem entity's shares	C
Payments of other equity instruments	0
Proceeds from exercise of stock options	0
Proceeds from issuing debentures notes bonds etc	

Proceeds from borrowings	8.55
Repayments of borrowings	0
Payments of finance lease liabilities	0
Payments of lease liabilities	0
Dividends paid	0
Interest paid	0
Income taxes paid (refund)	0
Other inflows (outflows) of cash	0
Net cash flows from (used in) financing activities	8.55
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	-0.04
Effect of exchange rate changes on cash and cash equivalents	
Effect of exchange rate changes on cash and cash equivalents	0
Net increase (decrease) in cash and cash equivalents	-0.04
Cash and cash equivalents cash flow statement at beginning of period	0.91
Cash and cash equivalents cash flow statement at end of period	0.87

Firefox





Date: 31-01-2023

To BSELimited, PhirozeJeeJeebhoy Towers, Dalal Street, MUMBAI – 400 001.

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on 31-01-2023

Unit: Hindustan Bio Sciences Limited (Scrip Code: 532041)

With reference to the subject cited, this is to inform the exchange that at the Board Meeting of Hindustan Bio Sciences Limited held on Tuesday, the 31st day of January, 2023 at 02.00 p.m. at the registered office of the company at Plot No.31, Sagar Society, Road No.2, Banjarahilis, Hyderabad-500034, Telangana, the following were considered and approved:

- Un-audited financial results of the company for the quarter ended 31st December, 2022 (enclosed as annexure)
- Limited Review Report for the quarter ended 31st December, 2022. (enclosed as annexure)
- The Resignation submitted by Mr. Varuna Varma Jampana Director of the Company is accepted.

The meeting concluded at 3.00 PM

Thanking you

Yours faithfully, For Hindustan Bio Sciences Limited Sci Hydershad

VENKATA RAMA MOHAN RAHUJAMPANA Managing Director (DIN: 00060800)

HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2, Banjara Hills, Hyderabad - 500 034, INDIA.

HINDUSTAN BIO SCIENCES LIMITED Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034 Phone No. 23555151 Fax 40205171

	STATEMENT OF UN AUDITED RESULTS FOR THE QUARTER AND NIN		and a second	CMBCH, 202		(Rs. In lakhs	
St.	same conservations	Quarter ended Nine Months Ended		Year ended			
No.	Particulars	31.12.2022 (Unaudited)	30.09.2022 (Unaudited)	31.12.2021 (Unaudited)	31.12.2022 (Unaudited)	1227-01000-0121	31.03.2022 (Audited)
1	Income from Operations	(one of the other	(contractory)	10.00000000		And the second second	
1	(a) Revenue from operations	31.81		23.96	68.95	43.38	43.0
	(b) Other Income					5.24	0.000
1	Total Revenue (1)	31.81		23.96	58.95	48.62	43.0
2	Expenses			10.000	0.353550	110083055	
•	(a) cost of material consumed					52.1	
	(b) Purchases of Stock -in-trade	18.29	2	15.90	36.58	28.93	23.6
	(c) Changes in inventories of finished goods,Stock -					1.2246.20	200200
	in-Trade and Work-in-Progress						
	(d) Employee Benefit Expenses	5.96	6.12	5.93	18.01	18.11	24.0
	(e) Finance Costs	0.11	0.06	0.13	0.20	0.28	0.5
		0.67	0.00	0.38	0.90	0.61	0.6
	(f) Selling Expenses	0.07	0.11	0.08	0.32	0.24	0.3
	(g) Depreciation and amortisation Expenses	2.01	1.20	1.74	8.18	13.72	45.3
	(h) Other Expenses	225205-02	7.49	24.15	64.19	61.89	94.5
	Total Expenses(2)	27.05	11118	(0.20)	(5.24)	(13.27)	(51.4
3	Profit/(Loss) before Exceptional& Extraordinary Items and tax (1 -2)	4.75	(7.49)	(0.20)	(0.24)	(13.27)	(array
4	Exceptional items	1.1.1	(7 40)	40.001	(5.24)	(13.27)	(51.4
5	Profit/(Loss) before tax(3 -4)	4.76	(7.49)	(0.20)	(0.24)	(in any	101.4
6	Tax Expenses	7.55	1.1.1		1 8	12	
	(a) Current Tax					0.03	0.0
	(b) previous Taxes				(B)	0.03	0.3
-	(b) Deferred Tax	1.1.1		0.000		42.24	200300
7	Profit /(Loss) for the period from continuing operations(5-6)	4.76	(7.49)	(0.20)	(5.24)	(13.24)	(51.7
8	Profit /(Loss) from discontinued operations					2	
9	Tax Expense of discontinued operations			-			
10	Profit /Loss from Discontinued operations after tax(8-9)						
11	Profit/(Loss) for the period(7+10)	4.76	(7.49)	(0_20)	(5.24)	(13.24)	(51.7
12	Other Comprehensive Income						
	A (1) Items that will not be reclassified to profit or loss		· · ·				
	(2) Income tax relating to items that will not be re-	1.0					
	classified to profit or loss		*	•			
	B (1) Items that will be reclassified to profit or loss		*	•			
	(2) Income tax relating to items that will be reclassified		*				
	to profit or loss	1.0					
13	Total Comprehensive Income for the period (11+12)	4.76	(7.49)	(0.20)	(5.24)	(13.24)	(51.7
	(comprising Profit (Loss) and other comprehensive income for the period		1212/2010		0400 0403 A		1010000
14	Paid up Equity Capital(Face value of Rs. 10/- each)	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08	1,025.0
15	Reserves excluding Revaluation Reserves as per balance sheet of						
	previous accounting year						(946.3
16	Earnings per equity share for continuing operations						1.228
	(A) Basic	0.05	(0.07)	100000000000000000000000000000000000000		1 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1	
	(B) Diluted	0.05	(0.07)	(0.00)	(0.05)	(0.13)	(0.5
17	Earnings per equity share for discontinuing operations						rand bo
	(A) Basic						
	(B) Diluted					1.1	
18	Earnings per equity share(for discontinuing & continuing operations						
	(A) Basic	0.05	(0.07)	(0.00)	(0.05)	(0.13)	
	(B) Diluted	0.05	(0.07)	(0.00)	(0.06)	(0.13)	(0.5

1 The Un Audited Financial Results were taken on record by the Board of Directors in their meeting held on 31.01.2023

2 Previous Year figures have been regrouped wherever necessary.

Placi Hyderabad Date 31.01.2023

or Hindustay BRI Sc mited Sei NS. . VENKATA RAMA MOHAN RAJU JAMPANA Hyderal Managing Director (DIN:00060800)

0

*

Clan,

VASG & ASSO CIATES Chartered Accountants

50374, 500 Figer, Rubers Towers Nonsyanigpida, Hyderated - 500 020, En (240 altgated) / 1848 / 772 E Inst. Introdyced-calcom Vesgeneration/figered-calcom

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEWOF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF M/S HINDUSTAN BIO SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/S. **HINDUSTAN BIOSCIENCES LIMITED** (the "Company"), for the quarter and period ended December 31,2022, being prepared by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended.

The preparation of this statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('IND AS 34), prescribed under section 133 of the companies act, 2013 read with relevant rules issued thereunder and other accounting principles generallyaccepted in India is the responsibility of the company's management and has been approved by the Board of Directors of the company, our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. Areview is limited primarily to inquiries of company personnel and an analytical procedure applied to financialdata and thus provides less assurance than an audit, we have not performed an audit and accordingly, we donot express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that theaccompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VASG & ASSOCIATES

Chartered Accountants FRN: 006070S

FRM 005070 AUG ED ACCS

1550

(A. Viswanatha Rao) Partner M.No:029597 UDIN: 23029597BGTFNU8619 Date:31/01/2023



Date: 01.10.2022 To, BSE Limited P.J.Towers, Dalal Street Mumbai – 400001

Dear Sir,

Sub: Disclosure of Scrutinizer Report and Voting Results of the 30th Annual General Meeting (AGM) of the Company held on Friday, 30th September 2022 in compliance with Regulation 44 of the SEBI (LODR) Regulations, 2015 and Rule 30 Sub-Rule 4 of Companies (Management and Administration) Rule 2014

We would like to inform that at the 30th Annual General Meeting (AGM) of the Company held on Friday, 30th September 2022 at 10.00 a.m at Plot No.31 Sagar society, Road No 2, Banjara Hills Hyderabad – 500034 all the items of business contained in the Notice of the AGM were transacted and approved by the members with requisite majority.

The details of the combined voting results (which includes the results of remote e-voting and Ballot Forms at the Annual General Meeting) in the format prescribed under Regulation 44(3) of the SEBI (LODR) regulation, 2015 along with Scrutinizer's Report are enclosed.

Yours faithfully Sci For Hindustan B ences ited J Varun Varma Director

HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2, Banjara Hills, Hyderabad - 500 034, INDIA.



3-5-943, Flat No. 208, Kubera Towers, Narayanaguda, Hyderabad - 500 029. Mobile : 98497 34349 Email : vbssprasad@gmail.com

P No. 4605

"SCRUTINIZER'S REPORT"

[Pursuant to Section 108 of the Companies Act, 2013] [Rule 20 (xi) of the Companies (Management and Administration) Rules, 2014]

Date:30.09.2022

The Chairman, HINDUSTAN BIO SCIENCES LIMITED H No.8-2-269/S, Plot No.31, Sagar Co-Operative Housing Society, Road No.2, Banjara Hills, Hyderabad - 500 034. Telangana

UDIN number F004139D001093821

Dear Sir.

To

I, VBSS PRASAD, appointed as scrutinizer for the purpose of scrutinizing the E-voting process of HINDUSTAN BIO SCIENCES LIMITED(CIN: L26942TG1991PLC013564) in a fair and transparent manner, for the below mentioned resolution(s) as contained in the Notice of the 30th Annual General Meeting (AGM) of the Company held on 30th September, 2022, I submit my report on e-voting results as under:

- 1. The e-voting services were provided by Central Depository Services (India) Limited.
- 2. Voting period commenced from 09.00 AM IST on 27.09.2022 and concluded on 5.00 PM on 29.09.2022
- 3. The Shareholders holding shares on the "Cut-off date" i.e., 23rd September 2022, were entitled to vote on the proposed resolutions stated in the Notice of the Company.
- 4. The votes were finalized on 30th September, 2022 at 12:00 Noon, from CDSL Website in the presence of two witnesses.
- 5. The results of e-voting along with the list of shareholders who voted "FOR" and "AGAINST" the below resolutions were downloaded from the e-voting website of CDSL. Falad



3-5-943, Flat No. 208, Kubera Towers Narayanaguda, Hyderabad - 500 029. Mobile : 98497 34349 Email : vbssprasad@gmail.com

Date:30.09.2022

To The Chairman, HINDUSTAN BIO SCIENCES LIMITED H.No.8-2-269/S, Plot No.31, Sagar Co-Operative Housing Society. Road No.2, Banjara Hills. Hyderabad – 500 034. Telangana

Dear Sir.

Sub: Scrutinizers' Report on e-voting conducted in pursuant to the provision of Section 108 of the Companies Act, 2013 (the Act) read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (the rule)

I refer to my appointment as scrutinizer made on 27thMay. 2022. pursuant to the authority granted by the Board of Directors of **HINDUSTAN BIO SCIENCES LIMITED** (The Company) to Scrutinize the e-voting process in a fair and transparent manner as per the provision of Companies Act. 2013 and Rules made there under for the 30thAnnual General Meeting (AGM) of the Company to be held on 30th September, 2022 at 10.00 A.M. at the registered office of the Company by physical presence and concluded at 10.20 AM.

I have carried out the work as Scrutinizer from the close of Annual General Meeting on 30th September, 2022. I had scrutinized and reviewed the voting through electronic means and votes tendered there in.

My responsibility as a scrutinizer for the e-voting process is restricted to make a scrutinizers' report of the votes cast in 'Favour' or 'Against' the resolution stated in the Notice of the AGM, based on the reports generated in the e-voting system provided by CDSL, the authorized agency to provide e-voting facility and engaged by the Company.

I herewith submit the scrutinizer's report on the results of the c-voting along with the relevant listings.

FES 4139 CP No. 4605 eny 34

ORDINARY BUSINESS:

Resolution 1:Ordinary Resolution

To receive, consider and adopt the Audited Balance Sheet as at 31st March 2022, the statement of Profit and Loss together with the Notes and Cash Flow Statement for the year ended on that date together with the Notes attached thereto, along with the Report of Auditors and Directors thereon.

Category	Mode of Voting	Members Present (1)	No. of shares held(2)	No. of votes polled (3)	% of Votes Polled on outstanding shares (4)=[(3)/(2)] * 100	No of Members voted in favour	No. of Votes — in favour (5)	No of Members voted against		% of Votes in favour on votes polled (6)=[(5)/(3)]*100	% of Votes against on votes polled (7)=[(6)/(3)]*1 00
	Remote E-Voting	2	962691	962691	100	2	962691	0	0	100	
	E-Voting	0	0	0	0	0	0	0	0	0	0
Promoter Group	Physical Voting	2	286915	286915	100	2	286915	0	0	100	0
	Total	4	1249606	1249606	100	4	1249606	0	0	100	
	Remote E-Voting	0	0	0	0	0	0	0	0	0	0
	E- voting	0	0	0	0	0	0	0	0	0	0
Public-	Physical Voting	0	0	0	0	0	0	0	0	0	0
Institutions	Total	0	0	0	0	0	0	0	0	0	0
	Remote E-Voting	37	146202	146202	100	33	145712	4	490	99.66	0.34
Public - Non-	E-Voting	0	0	0	100		145/12	0	450	35.00	0.54
Institutions	Physical Voting	18	687386	687386	100	18	687386	0	0	100	0
Fotal	Total	55	833588	833588	100	51	833098	4	490		
Grand Total		59	2083194	2083194	100	55	2082704	4	490		

Resolution was passed with requisite Majority

\$ abed = PRAS + FCS 4139 + CP No. 4605

Resolution 2:Ordinary Resolution

To appoint a Director in place of Mr. JampanaVarunVarma(DIN: 00515430), who retires by rotation and being eligible, offers himself for re-appointment.

Category	Mode of Voting	Members Present (1)	No. of shares held(2)	No. of votes polled (3)	Polled on outstanding shares	No of Members voted in favour	No. of Votes — in favour (5)	No of Members voted against	No. of Votes – against (6)	% of Votes in favour on votes polled (6)=[(5)/(3}]*100	% of Votes against on votes polled (7)=[(6)/(3)]*1 00
	Remote E-Voting	2	962691	962691	100.00	2	962691	0	0	100.00	
Promoter and	E-Voting	0	0	0	0.00	0	0	0	0	0.00	0.00
Promoter Group	Physical Voting	2	286915	286915	100.00	2	286915	0	0	100.00	0.00
on and a second seco	Total	4	1249606	1249606	100.00	4	1249606	0	0	100.00	0.00
	Remote E-Voting	0	0	0	0.00	0	0	0	0	0.00	0.00
	E- voting	0	0	0	0.00	0	0	0	0	0.00	0.00
Public-	Physical Voting	0	0	0	0.00	0	0	0	0	0.00	0.00
Institutions	Total	0	0	0	0.00	0	0	0	0	0.00	0.00
	Remote E-Voting	37	146202	146202	100.00	32	145706	5	496	99.66	0.34
Public - Non-	E-Voting	0	0	0	0.00	0	0	0	0	0.00	0.00
Institutions	Physical Voting	18	687386	687386	100.00	18	687386	0	0	100.00	0.00
Total	Total	55	833588	833588	100.00	50	833092	5	496	99.94	0.06
Grand Total		59	2083194	2083194	100.00	54	2082698	5	496	99.98	0.02

Resolution was passed with requisite Majority



Resolution 3: Ordinary Resolution

Appointment of Statutory Auditors

					% of Votes Polled on	No of Members		No of			% of Votes
Category	Mode of Voting	Members Present (1)	No. of shares held(2)	No. of votes polled (3)	shares			Members voted against	No. of Votes – against (6)	% of Votes in favour on votes polled (6)=[(5)/(3)]*100	against on votes polled (7)=[(6)/(3)]*1 00
	Remote E-Voting	2	962691	No. of Concession, Name of Street, or other	100.00	2	962691	0	0	100.00	0.00
Promoter and	E-Voting	0	0	0	0.00		0	0	0	0.00	0.00
Promoter Group	Physical Voting	2	286915	286915			286915	0	0	100.00	0.00
	Total	4	1249606		-	4	1249606	0	0	100.00	0.00
	Remote E-Voting	0	0	0	0.00	0	0	0	0		
lanan II	E- voting	0	0	0	0.00	0	0	0	0	0.00	
	Physical Voting	0	0	0	0.00	0	0	0	0	0.00	0.00
Institutions	Total	0	0	0	0.00	0	0	0	0	0.00	
	Remote E-Voting	37	146202	146202	100.00	33	145712	4	490		
	E-Voting	0	0	0	0.00	0		0	0	0.00	0.00
	Physical Voting	18	687386	687386	100.00	18		0	0		
the second s	Total	55	833588	833588	100.00	51	- Incompany of the	4	490		
Grand Total	read with a star	59	2083194	2083194	100.00	55	and the second sec	4	490		

Resolution was passed with requisite Majority



CONSOLIDATED RESULTS

ORDINARY BUSINESS:

Resolution 1:Ordinary Resolution

To receive, consider and adopt the Audited Balance Sheet as at 31st March 2022, the statement of Profit and Loss together with the Notes and Cash Flow Statement for the year ended on that date together with the Notes attached thereto, along with the Report of Auditors and Directors thereon.

Particulars	Remote E-voting		Voting at the AGM E- Voting		Physical Voting		Total Voting		Percentag e (%)
	Members present	Votes	Members present	Votes	Members present	Votes	Members present	Votes	
Assent	35	1108403	0	0	20	974301	55	2082704	100.00
Dissent	4	490	0	0	0	0	4	490	0.00
Total	39	1108893	0	0	20	974301	59	2083194	100

para la CP 116, 4605

Resolution 2:Ordinary Resolution

To appoint a Director in place of Mr. JampanaVarunVarma(DIN: 00515430), who retires by rotation and being eligible, offers himself for re-appointment.

Particulars	Remote E-vo	ting	Voting at th Voti		Physical	Voting	Total	Voting	Percentag (%)
	Members present	Votes	Members present	Votes	Members present	Votes	Members present	Votes	
Assent	34	1108397	0	0	20	974301	54	2082698	100.00
Dissent	5	496	0	0	0	0	5	496	0.00
Total	39	1108893	0	0	20	974301	59	2083194	100

Resolution 3: Ordinary Resolution

Appointment of Statutory Auditors

Particulars	Remote E-vo	ting	Voting at th Voti		Physical	Voting	Total	Voting	Percentag (%)
	Members present	Votes	Members present	Votes	Members present	Votes	Members present	Votes	
Assent	35	1108403	0	0	20	974301	55	2082704	100.00
Dissent	4	490	0	0	0	0	4	490	0.00
Total	39	1108893	0	0	20	974301	59	2083194	100

CS V.B.S.S. PRASAD, F.C.S.,B.L. COMPANY SECRETARY M.No. FCS4139, CP No. 4605, 208, Kubera Towers, Narayanaguda, Hyderabad - 500 029, Cell: 9849734349,





Date: 12.01.2023

To,

BSE Limited P. J. Towers, Dalal Street Mumbai – 400001

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Ref: Hindustan Bio Sciences Limited (Scrip Code: 532041)

Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that Mr. Varun Varma Jampana (DIN No: 00515430) Non Executive-Non Independent Director of the company, vide his letter dated 12th January 2023 has tendered his resignation as Non Executive-Non Independent Director of the Company with effect from 12th January 2023.

The resignation letter with reason as indicated is enclosed as Annexure A.

This is for the kind information and records of the Exchange, please

Thanking you.

For and on behalf of Hindustan Bio Sciences Limited

Venkata Rama Mohan Raju Jampana

Managing Director (DIN: 00060800)

Scie,

HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2, Banjara Hills, Hyderabad - 500 034, INDIA.

Date: 12th January 2023

To The Board of Directors Hindustan Bio Sciences Limited Plot No. 31, Sagar Society, Road No.2, Banjara Hills Hyderabad TG 500034

Dear Sir/Madam,

Sub: Resignation from the Directorship - Reg.

I, the undersigned, hereby tender my resignation from the Directorship of the Company with effect from 12th January 2023. Kindly accept my resignation with effect from 12th January 2023, from the post of Director of Hindustan Bio Sciences Limited, and relieve me of my duties.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary forms with the office of the Registrar of Companies to that effect.

Thanking You,

Yours Faithfully,

Varun Varma Jampana Director DIN No: 00515430



To **BSE Limited.** Phiroze JeeJeebhoy Towers, Dalal Street, MUMBAI - 400 001.

Date: 07-04-2023

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Unit: Hindustan Bio Sciences Limited (Scrip Code: 532041)

With reference to the subject cited and pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Mrs. Mansa Thakur (A67140) Company Secretary of the Company has tendered her resignation from the post of the Company Secretray and Compliance Officer of the Company with effect from April 7, 2023.

Her Successor shall be appointed in due course, within the time limits prescribed under the provisions of the Companies Act, 2013 and Rules made thereunder read with the applicable provisions of the Listing Regulations and the Same shall be duly intimated to Stock Exchange.

We request you to kindly take the same on record.

This is for your information.

Thanking you

Yours faithfully, For Hindustan Bio Sciences Limited

VENKATA RAMA MOHAN RAJU JAMPANA Managing Director (DIN: 00060800)

HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2, Banjara Hills, Hyderabad - 500 034, INDIA.





Annexure I

Sr. No,	Details of events that need to be provided	Information of such event			
1	Reason of Change Viz. Appointment, Resignation, Removal, Death or otherwise	As mentioned in the Resignation Letter of Mrs. Mansa Thakur dated: 07.04.2023			
2	Date of Appointment/ Cessation (as applicable) & term of Appointment	07.04.2023			
3	Brief Profile	NA			
4	Disclosure of relationship between director (in case of Appointment of a Director)	NA			

HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2, Banjara Hills, Hyderabad - 500 034, INDIA.

RESIGNATION LETTER

Date: 07.04.2023

To, The Board of Directors, Hindustan Bio Sciences Limited, Hyderabad.

Subject: Resignation from the post of Company Secretary and Compliance Officer -reg.,

Dear Sir/Madam,

This is to inform you that I, Mansa Thakur, hereby tender my resignation from the post of Company Secretary and Compliance officer of the Company with effect from April 7, 2023. The Board is kindly requested to accept my resignation and take the same on your records.

I would like to thank the Board and the fellow members for the support and co-operation extended during my tenure as Company Secretary.

I extend my best wishes to the Company for its future endeavors.

Thanking You, Yours Sincerely,

(Mansa Thakur) M. No: A67140



VASG & ASSOCIATES Chartered Accountants

503/A, 58 Floor, Kubera Towers, Narayanaguda, Hydenabod - 500 029 PN - 040-66840600 / 66887732 E-mail - Info@vie.g-ca.com vasgassociates@gmail.com

Auditors Consent and Certificate (Pursuant to the provisions of Section 139 of Chapter X of the Companies Act, 2013)

Date: 25/07/2022

To The Board of Directors HINDUSTAN BIO SCIENCES LIMITED PLOT NO.31SAGAR SOCIETY ROAD NO.2, BANJARAHILLS HYDERABAD TG 500034

Dear Sir(s),

In connection with our appointment as statutory auditors of M/s. HINDUSTAN BIO SCIENCES LIMITED ("the Company") for a period of 5 years ie from the financial year 2022-23 to 2026-27 in accordance with the provisions of the Companies Act, 2013 ("the Act") and The Companies (Audit and Auditors) Rules, 2014 ("the Rules"), I the undersigned, hereby certify that:

- We hereby give our consent to be appointed as Statutory Auditors of the Company u/s 139(6) of the Act.
- Our firm is eligible to be appointed as auditor, and has not incurred any disqualifications under the Act;
- Our firm is not disqualified for appointment under the provisions of Chartered Accountants Act, 1949 and rules and regulations made there under;
- 4. the proposed appointment is as per the terms provided under the Act;
- the proposed appointment is within the limits laid down by or under the authority of the Act;
- No orders have been issued and there are no proceedings pending against the firm with respect to professional matters of conduct before the Institute of Chartered Accountants of India, any competent authority, or any court.
- We hereby declare that the appointment, if made shall be in accordance with the conditions as prescribed under Rule 4(1) of the Companies (Audit and Auditors) Rules, 2014 and as provided in section 141 of Companies Act 2013.

Thanking You

Yours Faithfully, For VASG and ASSOCIATES Chartered Accountants Firm Registration No: 006070S Chartered Accountants (A VISWANATHA RAO) Partner Membership Number: 029597





CERTIFIED TRUE COPY OF THE RESOLUTION PASSED AT THE MEETING OF THE ANNUAL GENERAL MEETING OF THE COMPANY HELD ON 30-09-2022 AT 10:00 A.M. AT THE REGISTERED OFFICE OF THE COMPANY

Ordinary Business:

Ordinary Resolution:

ITEM No: 03 Appointment of Statutory Auditor of the Company:

"RESOLVED THAT pursuant to the provisions of Section 139, 142 and other applicable provisions of the Companies Act, 2013, if any, read with the Companies (Audit & Auditors) Rules, 2014, including any statutory enactment or modification thereof, and pursuant to the recommendations of the audit committee and the board of directors of the company M/s. VASG & Associates., Chartered Accountants, (Firm Registration No. 006070S),Hyderabad be and is hereby appointed as the Statutory Auditors of the company to conduct the Statutory Audit of the company for a period of 5 years ie from the conclusion of 30th Annual General Meeting to the conclusion of 35th Annual General Meeting of the company to be held in the year 2027 on such remuneration as may be decided by the Board of Directors in consultation with the Statutory Auditors of the Company."

"RESOLVED THAT any director of the company be and is hereby authorized to do all the acts, deeds and things as may be necessary for accomplishing the above stated resolution.

For HINDUSTAN BIO SCIENCES LIMITED

Bio Scie Hyderaba J Varun Varma Director (DIN: 0051543

Place: Hyderabad Date: 10-10-2022

HINDUSTAN BIOSCIENCES LTD.

#31, Sagar Society, Road No. 2, Banjara Hills, Hyderabad - 500 034, INDIA.

IN THE NATIONAL COMPANY LAW TRIBUNAL HYDERABAD BENCH-II

CA 52/66/HDB/2021

[Application under Section 66 of the Companies Act, 2013 r/w Rule 2 of the National Company Law Tribunal (Procedure for Reduction of Share Capital of Company) Rules, 2016

M/s. Hindustan Bio Sciences Limited Registered Office: Plot No.31, Sagar Society Road No.2, Banjara Hills Hyderabad – 500 034 Represented by its Managing Director Mr. Venkata Rama Mohan Raju Jampana

FREE OF COST COPY

and a subarra

...Applicant Company

Date of order: 06.01.2023

Hon'ble Justice Smt. Telaprolu Rajani, Member (Judicial) Hon'ble Shri Charan Singh, Member (Technical)

Counsel/Parties present:

For the Petitioner

: Mr. Vivek Surana, PCS

For the RD

বিষি

Company Las

3120

derabad Secoram:

: Mr. Shashi Raj Dara, ICLS

Heard on: 03.01.2023

Jas

NCLT - Hyd. Bench -II CA 52/66/HDB/2021 Date of Order: 06.01.2023

12aus

[PER: BENCH]

ORDER

- I. The instant Company Application has been filed on behalf of the Applicant Company under Section 66 r/w Rule 2 of the National Company Law Tribunal (Procedure for Reduction of Share Capital of the Company Rules), 2016 for the purpose of Reduction of Share Capital in pursuance of the Board Resolution dated 01.08.2018.
- II. The gist of the Applicant Company's petition, in brief is as follows –
- M/s. Hindustan Bio Sciences Limited, for short, 'the Company' was originally incorporated under the provisions of the Companies Act, 1956, under the name and style "Garuda Cements Limited", on 16.12.1991. Subsequently, the Company changed its name to M/s.Hindustan Softel Limited on 10.11.2000 and further changed its name to M/s.Hindustan Bio Sciences Limited on 27.08.2001, after complying with the necessary provisions under the Companies Act, 1956 and obtained a fresh Certificate of Incorporation from the Registrar of Companies, Andhra Pradesh, having CIN No. L26942TG1991PLC013564. A copy

1

विधि

smany Las

आधेव

NCLT - Hyd. Bench -II CA 52/66/HDB/2021 Date of Order: 06.01.2023

of the Certificate of Incorporation and Fresh Certificate of Incorporation of the Company is filed as Annexure - 1 of the application.

- The Registered Office of the Company is situated at Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad- 500034, Telangana and is carrying on the business
 - a) To establish, acquire, promote, run, manage, lease and enter into strategic alliances with domestic companies, international companies, institutions, to manufacture, market, distribute, sell, export, import and other-wise deal in all types of chemicals, pharmaceuticals, Biopharmaceuticals, gene-related products, genetic informatics proteomics, diagnostic reagents, diagnostic kits, lifesaving drugs etc.;



b) To carry on the business of consulting engineers in chemical, pharmaceutical, biopharmaceuticals, bio-engineers, dyestuff industries and to develop, establish, run, educational and training centers and research development, clinical train investigations and related matters in the field of Bio-technology.

Jon

3

NCLT - Hyd. Bench -II CA 52/66/HDB/2021 Date of Order: 06.01.2023

- c) To develop, manufacture process, convert, produce, service, invent, prepare, own make use of, buy, sell, import, export, lease, deal, distribute and market compute software and allied products.
- d) To extract, produce, refine, process, buy, sell import or otherwise engage or deal in all types of chemicals, bulk drugs intermediates and any other commodities or products.

A copy of the Memorandum and Articles of Association of the Company is filed as Annexure -1 of the application.

iii. The Authorized Share Capital of the Company as on 31.03.2021 is Rs.11,00,00,000/- (Rupees Eleven Crores only) divided into 1,10,00,000 (One Crore and 378 Company Law Ten Lakhs only) Equity Shares of Rs. 10/- (Rupees Ten only) each. The Issued, Subscribed and Paid-up Share gapital of the Company is Rs.10,25,08,000/-(Rupees Ten Crores Twenty Five Lakhs Eight Grabad Thousand only) divided into 1,02,50,800 (One Crore Two Lakhs Fifty Thousand Eight Hundred only) fully paid up equity shares of Rs.10/- (Rupees Ten only) each.

4

यधि

New

As per Article 59 of the Articles of Association of the iv. Company, the Company is authorized to reduce its Share Capital and Securities Premium Account in any manner permitted by law, from time to time, by a special resolution. Article 59 of the Articles of Association of the Company is reproduced below:

"59.The Company may, by Special Resolution, reduce in any manner and with. and subject to, any incident authorised and consent required by law,

a) Its share capital b) Any capital redemption reserve account or c) Any share premium account"

The brief financial position of the Company is as v.

	Particulars	THE REAL PROPERTY OF	(Amount i	n Rupees)	the state
व्यक्ती विधि आ		30.06. 2021	31.03.2021	31.03.2020	31.03.2019
An Company Law	Share Capital – 1,02,50,800 equity shares of Rs.10/- each	10,25,08,000	10,25,08,000	10,25,08,000	10,25,08,000
	Securities Premium				-
८ रिग्रमाद न्य	Serves	(9,02,16,200)	(8,94,62,039)	(8,00,63,554)	(80,872,280)
aderabad	Turnover	19,42,181	1,03,19,225	1,94,33,088	3,56,40,194
	Net Profit / Loss for the year	(7,54,161)	(93,98,485)	8,08,726	10,99,679
	Accumulated Profit / Losses	(9,02,16,200)	(8,94,62,039)	(8,00,63,554)	(80,872,280)
	Networth	1,22,91,800	1,30,45,961	2,24,44,446	21,635,720

follows:



New

A copy of the Audited Financial Statements as on 31.03.2021 and Unaudited Financial Statements of the Company for the quarter ending by 30.06.2021 are filed as "Annexure -2A and 2B" respectively.

- vi. The Board of Directors of the Company at its Board Meeting held on 08.08.2018, after evaluating various options, has decided to reduce 80% of the paid-up share capital of the Company by cancelling and extinguishing 80% of the paid-up value of the shares and retaining Rs.2/- per share.
- vii. After an analysis of the various options available to the Company, the Board felt that the restructuring of the Company's existing capital structure becomes imperative. The reduction in the paid up equity share capital by writing off the entire accumulated losses is the most practical and economically efficient option available to the Company and it approved the proposal of reducing the paid up equity share capital of the Company to the extent of 80% in accordance with the provisions of the Companies Act, 2013.
 - viii. The accumulated losses of the Company as on 30.06.2021, amounted to Rs.9,02,16,200 (Rupees Nine Crores Two Lakhs Sixteen Thousand and Two

Der

hundred only), out of which, Rs.8,20,06,400/- will be written off against the paid up equity share capital of the Company by reducing the face value of Rs.8/each from 1,02,50,800 (One Crore Two Lakhs Fifty Thousand Eight Hundred only) fully paid up equity shares of Rs.10/- (Rupees Ten only) each aggregating to Rs.8,20,06,400 (Rupees Eight Crores Twenty Lakhs six Thousand and Four hundred only).

ix. After the writing off of the accumulated losses by way of reduction in the paid up share capital of the Company, the paid up Equity share capital shall be Rs.2,05,01,600/- (Rupees Two Crores Five Lakhs one Thousand Six Hundred Only) divided into 1,02,50,800 (One Crore Two Lakhs Fifty Thousand Eight Hundred only) fully paid up equity shares of Rs.2/- (Rupees two only) each.

> After the aforesaid reduction, the paid up equity share capital of the Company shall be reduced from Rs.10,25,08,000/- (Rupees Ten Crores Twenty-Five Lakhs and Eight Thousand only) divided into 1,02,50,800 (One Crore Two Lakhs Fifty Thousand and Eight Hundred only) Equity shares of Rs.10/-(Rupees Ten only) each to Rs.2,05,01,600/- (Rupees Two Crores Five Lakhs one thousand and six hundred

> > 7

Jerabed

New

only) divided into 1,02,50,800 (One Crore Two Lakhs Fifty Thousand and Eight Hundred only) Equity shares of Rs.2/- (Rupees Two only) each, by reducing the face value from Rs.10/- each to Rs.2/- each.

- xi. There will be no fractional shares on account of reduction of capital. There will be only reduction in the face value per share from Rs.10/- per equity share to Rs.2/- per equity share.
- xii. The reduction in the paid up equity share capital by way of writing off the entire accumulated losses will be effected as given in the following table:

ती विधि npany (

Brahad

S1. No.	Particulars	Amount As on 30.06.2021
Α.	Amount of total accumulated losses	9,02,16,200
В.	Less: amount available in the securities premium account	
C.	Balance of accumulated losses (A-B)	9,02,16,200
D.	Less: amount of accumulated losses proposed to be written-off against the paid up equity share capital 10250800 equity shares multiplied by face value of Rs.8/-)	8,20,06,400
E.	Therefore, balance of accumulated losses (C-D)	82,09,800
F.	Proposed reduction in the paid up share capital of the Company by writing off of the accumulated losses as above (1,02,50,800 equity shares multiplied by face value of Rs.8/-)	8,20,06,400

haves

The existing Share Capital of the Company, proposed xiii. reduction in the Share Capital by writing off of the accumulated losses and the paid up share capital post reduction of capital as on 30.06.2021 is as follows:

Particulars	Existing Share Capital Details			Proposed Reduction in the Share Capital for writing off of accumulated losses				Post Reduction Share Capital Details				
	No. of shares	Fa ce Val ue	Total Capital	% of Holdi ng	No. of shares	Fac e Val ue	Total Capital	% of Holdin g	No. of shares	P ac e Va 1u	Total Capit al	% of Holdi ng
Promoter's & Promoter's Group	12,40,500	10	1,24,96,063	13.19	12,49,606		99,96,848	12.19	12,49,000	9	94,99,212	12.10
Institutions/ Mutual Funds etc	7	(F)		:#						Ŧ		
Public holding	WALTER .		8,00,11,010	(17.4)	10.00,100		Tananaay	87,61	96,65,894		1.40.02,746	17.51
Total	1,02,50,800	10	10,25,08,000	100	8,78,78,304	8	8,20,05,400	100	1,02,50,800	2	2,08,01,	100

The share capital and the shareholding pattern of the xiv. Company pre and post reduction as on 30.06.2021 is as follows:

Particulars	Manufacture (1996)	Pre Co	nsolidation	53. [PL: [M]		Post consolidation					
	No. of Shares Held	Face Value	Total Capital	% of Holding	No. of Shares Held	Face Value	Total Capital	% of Holding			
Promoter's of Promoter's Group	12,49,606	10	1,24,96,060	12.19	12,49,606	2	24,99,212	12.19			
Institutions/ Mutual Funds etc		11	<i></i>		**			64			
Public holding	90,01,194	10	9,00,11,940	87.81	90,01,194	2	1,80,02,388	87.81			
Total	1,02,50,800	10	10,25,08,000	100.00	1,02,50,800	2	2,05,01,600	100.00			



न्ती विधि

Ten

xv. Accordingly, a Special Resolution was passed by the shareholders of the Applicant Company at the Annual General Meeting held on 21.07.2021 approving the Scheme of Reduction of Share Capital, as follows-

"RESOLVED THAT pursuant to the provisions of Sections 66 and other applicable provisions of the Companies Act, 2013 ("the Act") and the rules made thereunder ("the Rules") (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and pursuant to Article 59 of the Articles of Association of the Company and subject to approval by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("NCLT"), approvals as may be required from the appropriate authorities, the consent of the shareholders of the Company be and is hereby accorded to the Scheme of Reduction of Capital of the Company by way of reduction of paid- up share capital of the Company from Rs.10,25,08,000/-(Rupees Ten crores twenty five lakhs and eight thousand only) divided into 1,02,50,800 (one crore two lakhs fifty thousand and eight hundred) equity shares of Rs 10/- (Rupees Ten only) each fully paid-up to Rs.2,05,01,600/- (Rupees Two crores five lakhs one thousand and six hundred only) divided into 1,02,50,800 (one crore two lakhs fifty thousand and



eight hundred) Equity shares of Rs.2/- (Rupees Two only) each fully paid-up by reducing face value of each equity share from Rs.10/- to Rs.2/- on the Effective Date of the draft Scheme of Reduction of Capital ("Scheme")."

"FURTHER RESOLVED THAT the Scheme providing Reduction of Share Capital of the Company as submitted to the BSE Limited (Stock Exchange) for observations and / or Securities and Exchange Board of India, be and is hereby approved."


"**RESOLVED FURTHER THAT** upon extinguishment of such share capital, the issued, subscribed and paid-up equity share capital of the Company shall stand reduced to the extent of the face of equity shares so extinguished on the Record date."



"RESOLVED FURTHER THAT after reduction of share capital the face value of each share will be Rs.2/- and the Board is authorized to issue revised share certificates in lieu of the cancelled physical certificates."

"RESOLVED FURTHER THAT subject to confirmation of the Scheme by NCLT, Hyderabad Bench, and all other approvals from any other appropriate authorities, the Company be and is hereby not required to add the words "And Reduced" to its name subsequent to such reduction of capital of the Company."

"RESOLVED FURTHER THAT the Board of Directors of the Company ("the Board"), the Chief Financial Officer and the Company Secretary be and are hereby authorized to take all necessary steps and do all such acts, deeds, matters and things, as they may, in their absolute discretion deem necessary, expedient, usual or proper in the best interest of the Company including issuing any directions for settling any question or doubt or difficulty whatsoever that may arise, for the purpose of giving effect to the reduction of capital, or to any modification thereof without being required to seek any further consent or approval of the members or otherwise."



त्विधि व्ययुद्ध

"RESOLVED FURTHER THAT Mr. Venkata Rama Mohan Raju Jampana, Managing Director, Mr. Varun Varma Jampana, Whole-Time Director, Ms. Kamala Tamada, Company Kumar Secretary and

Mr.Seshavataram Goli, CFO of the Company be and are hereby authorized jointly and severally to take all necessary steps for effecting the reduction of capital of the Company, including but not limited to:

- Finalizing, amending and settling the draft scheme, application / petition, and assent to such alterations, conditions and modifications, if any, or effect any other modification or amendment as the Board of Directors of the Company may consider necessary or desirable to give effect to the proposed reduction of share capital;
- Filing any affidavit, petition, pleading, application, form or reports before Hon'ble NCLT or any other statutory or regulatory authority including BSE Limited, SEBI, the Registrar of Companies, the Regional Director or such other authority as may be required in connection with the proposed reduction of capital or its sanction thereof and to do all such acts and deeds as they may deem necessary in connection therewith and incidental thereto;



 To make such alterations, modifications or amendments in all the applications, petitions and other documents as may be required or necessary for complying with the requirements or conditions imposed by the Hon'ble NCLT and/or any other appropriate authorities and to prepare and execute applications, petitions and file the same with the Hon'ble NCLT and/or any other appropriate authorities and to do all such matters connected therewith, as may be directed by the Hon'ble NCLT and/or other appropriate authorities, if any, and to appoint and retain services of such professionals as may be necessary in connection therewith including and to do all such acts, deeds, matters and things as may be required to bring the Reduction of Capital into effect:



Signing all applications, petitions, affidavits, undertakings, documents, letters relating to the proposed reduction of capital and represent the Company before the Hon'ble NCLT and any other authorities in relation to any matter relating to the proposed reduction of capital or delegate such authority to any other person through a valid power of attorney;

14

you

· To verify, sign, deal, swear, affirm, declare, deliver, execute, make, enter into, acknowledge, undertake, record all deeds, declarations, instruments, vakalatnamas. applications. petitions, affidavits, objections, notices and writings whatsoever as may be usual, necessary, proper or expedient and all manner of documents, petitions, affidavits and applications under the applicable laws including Companies Act, 2013, and Rules made thereunder and other applicable laws/regulations in relation to the aforesaid matter and to represent the Company in all correspondences, matters and proceedings and any nature whatsoever in relation to the above;



- To authenticate any document, instrument, proceeding and record of the Company;
 - Obtaining the requisite approval and/or consents of the shareholders, secured lenders of the Company, bank, financial institutions and other regulatory authorities or entities or agencies as may be required and for that purpose, to initiate all necessary actions and to

take other consequential steps as may be required from time to time in that behalf;

- To engage any counsel, consultant firms, advocates, attorneys, pleaders, solicitors, valuers. Company Secretary/Chartered Accountant/Cost Accountants in whole time practice, accountants, registrars or any other one or more agencies, as may be required in relation to or in connection with the proposed reduction of share capital, on such terms and conditions as they may deem fit, finalize fees, terms and conditions of their appointment letter(s), furnish such information as may be required by them and also to sign, execute and deliver all documents, letters, advertisements, announcements. disclosures. affidavits. undertakings and other related documents in favour of the concerned authorities, advocates or any one or more persons or firms as they may deem fit and to do all such acts, deeds and things as they may deem fit and as may be necessary in this regard;
- Incur such other expenses as may be necessary with regard to the above transaction, including

বিথি Gerab



payment of fees to Counsels, Registrars and other agencies and such other expenses that may be incidental to the above, as may be decided by them;

- Make any modifications as they may consider necessary in relation to the procedure and modalities of effecting the transactions contemplated in this resolution;
- To file requisite forms with the Registrar of Companies in connection with the proposed reduction of share capital during and after the process of sanction thereof;
- To give such directions as they may think fit and proper, including directions for settling any questions or difficulties that may arise and to do all acts, deeds and tasks, as may be deemed necessary, expedient or proper to give effect to the proposed reduction of capital and for matters connected therewith or incidental thereto;

A copy of the Board Resolution passed by the Board of Directors of the Applicant Company is filed as Annexure – 3 of the application.

17



XVI. CONSENT OF THE STOCK EXCHANGE (I.E. BSE LIMITED) AND SEBI

The Applicant Company is a Listed Company having its shares listed and traded on BSE Limited ('BSE'). In terms of the SEBI (LODR) Regulations, 2015 and the Circulars issued thereunder from time to time by the SEBI, the Applicant Company had filed an application with the BSE Limited along with a copy of the Scheme for obtaining Observation Letter / No Objection to the Scheme.

Bombay Stock Exchange ('BSE') has given its NoObjectionvideletterbearingDCS/AMAL/PB/R37/1969/2021-22,dated08.06.2021, with the following observations and replyfiled by the Applicant Company is as follows:

A COM	SLNo.		Reply filed by the Applicant Company
* * Acrierada	and	Company shall duly comply with various provisions of the SEBI Circular No.CFD/DIL3/CIR/2017/21, dated 10.03.2017	Complied
	2.	Company shall ensure that additional information, if any, submitted by the Company, after filing the Scheme with	Not Applicable

18

12 cra

क विधि अग्रि

	the Stock Exchanges, and from the date of receipt of this letter is displayed on the websites of the listed company and the stock exchanges.	
3.	Company is advised that the observations of SEBI/Stock Exchanges shall be incorporated in the petition to be filed before the National Company Law Tribunal (NCLT) and the company is obliged to bring the observations to the notice of NCLT.	Complied
4.	It is to be noted that the petitions are filed by the company before NCLT after processing and communication of comments/observations on draft scheme by SEBI/stock exchange. Hence, the company is not required to send notice for representation as mandated under section 230(5) of Companies Act, 2013 to SEBI again for its comments / observations / representations.	Complied

and share

Vderabi

It is averred that the Company has complied with the instructions/observations of BSE Limited of its letter dated 08.06.2021 and with compliances with respect to SEBI (LODR) Regulations, 2015.

nous

The Applicant Company undertakes that upon the approval of the Scheme of Reduction of Share Capital by this Hon'ble Tribunal, they shall comply with all the observations of BSE including –

- following the provisions of SEBI Act, Rules, Regulations, directions, bye-laws, circulars, notifications of the SEBI and any other statutory authority and Rules, Byelaws, and Regulations of the Exchange;
- Publishing the paper advertisements at appropriate times.

A copy of the Observation Letter issued by BSE is filed as "Annexure - 5" at page nos. 228 to 229 of the application.

ALTERATION OF MEMORANDUM OF ASSOCIATION AND ARTICLES OF ASSOCIATION OF THE COMPANY:

"**RESOLVED THAT** pursuant to Section 13, 14 and 61 of the Companies Act, 2013 and subject to approval of the Scheme of Reduction of Share Capital by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("NCLT"), the consent of the shareholders of the Company be and is hereby accorded to give effect to



has



the reduction in the face value of the Shares of the Company from Rs.10/- to Rs.2/- per share, the Authorised Share capital of the Company be altered from Rs. 11,00,00,000 (Rupees Eleven crores only) divided into 1,10,00,000 (one crore and Ten lakhs only) Equity Shares of Rs.10/- (Rupees Ten) each to Rs.11,00,00,000 (Rupees Eleven crores only) divided into 5,50,00,000 (Five crores and fifty Lakhs only) Equity Shares of Rs.2/- (Rupees Two) each and consequently the existing Clause V of the Memorandum of Association of the Company be and is hereby altered by deleting the same and substituting in its place and instead thereof, the following:



"Clause V: The Authorised Share Capital of the Company is Rs.11,00,00,000/- (Rupees Eleven Crores only) divided into 5,50,00,000 (Five Crores and Fifty Lakhs) Equity Shares of Rs.2/- (Rupees Two) each."

"RESOLVED FURTHER THAT pursuant to provisions of Section 14 of the Companies Act, 2013 and upon approval of the Scheme of Reduction of Share Capital by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("NCLT") the, existing Article 5 of

the Articles of Association of the Company be and is hereby altered by deleting the same and substituting in its place and instead thereof, the following:

"Article 5: The Authorised Share Capital of the Company is Rs.11,00,00,000 /-(Rupees Eleven Crores only) divided into 5,50,00,000 (Five Crores and Fifty Lakhs) Equity Shares of Rs.2/- (Rupees Two) each to be increased or reduced in accordance with the relevant provisions of the Companies Act, 2013."

"RESOLVED FURTHER THAT the Board be and is hereby authorized to do all such acts, deeds and things as may be necessary or expedient to give effect to this resolution."



A copy of the Special Resolutions passed by the Shareholders of the Applicant Company and a copy of the Minutes of the Annual General Meeting of the Shareholders of the Company are filed as "Annexure - 6&7" respectively.

xviii. In the AGM held on 21.07.2021, 51 members were present, out of which, 45 members, constituting 18.95% of total shares of the company voted. 42 members holding 19,42,522 shares, voted in favour of the resolution for reduction of share capital.

Yona

- xix. The reduction of the paid up equity share capital does not involve extinction or reduction of any liability in respect of unpaid capital as there are no partly paid shares. However, it envisages cancellation of the paidup share capital account to the extent of Rs.8,20,06,400 (Rupees Eight Crores Twenty Lakhs six Thousand and Four hundred only) which is lost and is unrepresented by available assets of the Company by writing off the same and setting it off towards the accumulated losses of the Company as on 30.06.2021.
- xx. All the Creditors have given their respective consent by way of individual affidavits to the Scheme, stating that they are well acquainted with the facts of the Scheme of Reduction of Share capital and that they do not have any objection to the proposed Scheme of Reduction of Share Capital of Hindustan Bio Sciences Limited and its Shareholders and Creditors. Copies are filed as Annexure-12 at page nos. 248 to 260 of the application.
 - xxi. The Company has five unsecured Creditors and there are no sundry creditors and secured creditors as on 31.08.2021 and the total amount due to such

23

Unsecured Creditors is Rs.2,06,46,938/- (Rupees Two Crores Six Lakhs Forty Six Thousand Nine Hundred and Thirty Eight only). A certificate on the List of Creditors duly certified by the Managing Director as on 31.08.2021 and a Certificate from the Auditor of the company are filed as "Annexures – 10 & 11 respectively.

xxii. The Company has not accepted any deposits and there are no arrears in the repayment of the deposits or the interest thereon. A copy of the Certificate issued by C. Ramachandram & Co., Chartered Accountants is filed as Annexure-13 at Page No.261 of the application.

xxiii. Accounting Treatment:

C. Ramachandram & Co., Chartered Accountants and Statutory Auditors of the Company have vide their Certificate dated 04.09.2021 certified that the factor of the aforesaid scheme is in compliance with SEBI (Listing Regulations and disclosure Requirements) Regulations, 2015 and circulars issued there under and all the applicable Indian Accounting Standards ("Ind AS") notified by the Central government under

the Companies Act, 2013. A copy of the Certificate is filed as Annexure-15 of the application at page no. 263 of the application.

- xxiv. An amount of Rs.8,20,06,400/- (Rupees Eight Crores Twenty Lakhs Six Thousand and Four Hundred only) will be reduced from the paid up equity share capital of the Company and the same will be set-off against the total accumulated losses of the Company as on 30.06.2021. The accounting treatment proposed is in conformity with the Accounting Standards as prescribed under the provisions of Section 133 of the Companies Act, 2013, read with relevant rules made thereunder and amended from time to time.
- xxv. It is further submitted that the proposed reduction in the paid up equity share capital will not prejudicially affect the Applicant Company or its shareholders and the proposed reduction would not in any way adversely affect the ordinary operations of the Company or the ability of the Company to honor its commitments or to pay its debts, if any, that may arise in the ordinary course of business.

25

বিচি

company (

- xxvi. The Company is solvent enough and has adequate funds to meet all its financial obligations and therefore the interest of the creditors, if any, shall not in any way be prejudicially affected.
- xxvii. No petition under Section 241 or 242 of the Companies Act, 2013, has been filed against the Applicant Company and there has been no material change in the affairs of any of the Applicant Company, except for what was done in the normal course of business. There are no proceedings pending under Section 210 to 227 of Companies Act, 2013, against the Applicant Company.
- xxviii. The Scheme of Reduction of Capital would not affect the employees and workers of the Company in any manner and their service shall be continuous and they would continue to enjoy the same benefits as they used to before the Reduction of Capital.

Neur

He Applicant Company filed an Affidavit of Service dated 18.10.2021 enclosing the acknowledgements of proof of service to all the creditors, Regional Director, Hyderabad, the Registrar of Companies, Hyderabad and also paper publication in "Business Standard", English Daily

newspaper and "Nava Telangana", Telugu Daily newspaper on 06.10.2021.

IV. Despite service of notice, the Registrar of Companies, Hyderabad did not file its report. The proviso of 66(2) of the Companies Act, 2013, states as follows:

"(2) The Tribunal shall give notice of every application made to it under sub-section (1) to the Central Government, ROC, Securities Exchange Board, in the case of listed companies, and the creditors of the company and shall take into consideration the representations, if any, made to it by that Government, Registrar, the Securities and Exchange Board of India and the creditors within a period of three months from the date of receipt of the notice.

Provided that where no representation has been received from the Central Government, Registrar, the Securities Exchange Board or the Creditors within the said period, it shall be presumed that they have no objection to the reduction".

Hence, the consent of the ROC is deemed as given.



The Regional Director, (South East Region), Ministry of Corporate Affairs, Hyderabad vide his report dated 18.01.2022 while reiterating the averments made in the Application has made certain observations. The observations of RD and the comments offered by the Applicant Company dated 24.06.2022 are given against each observation as under:-

Dars

Date of Order: 06.01.2023

Para Nos.	Regional Director's Report/observations	Reply Affidavit dated 28.10.2021 file
	Report/observations The Central Government represented by the Regional Director, South Eastern Region, Ministry of Corporate Affairs, Hyderabad has been served with the copy of Notice in Company Application No. 52/ 66/HDB/ 2021, pursuant to Section 66 of the Companies Act, 2013. The Registered office of the Petitioner Company is situated in the State of Telangana which is within the jurisdiction of this Hon'ble Tribunal. The main business activity of the Company is to establish, acquire, promote, run, manage, lease and enter into strategic alliances with domestic companies, institutions, to manufacture, market, distribute, sell, export, import and other wise deal	Reply Affidavit dated 28.10.2021 file by the Petitioner Companies
Page 2@ para 4	in all types of chemicals, pharmaceuticals, Bio- pharmaceuticals, gene related products etc. As per the Clause 59 Reduction of Share Capital etc. by the company, the Company may, by special resolution, reduce in any manner and with subject to any incident authorized and consent required by law (a) its share capital (b) any capital redemption reserve account or (c) any share premium account. The Applicant Company has passed special resolution for reduction of capital u/s 66 of the Companies Act, 2013, from Rs.10,25,08,000/- (Rupees Ten Crores Twenty Five Lakhs Eight Thousand only) divided into 1,02,50,800 (One Crore Two	

ব

der

Compan

you

Date of Order: 06.01.2023

	Lakhs Fifty Thousand Eight Hundred only) equity shares of Rs.10/- (Rupees Ten only) each fully paid upto Rs.2,05,01,600/- (Rupees Two Crores Five Lakhs One Thousand Six Hundred only) divided into 1,02,50,800/- (One Crore Two Lakhs Fifty Thousand Eight Hundred only) equity shares of Rs.2/- (Rupees Two only) each fully paid up by reducing face value of each equity shares from Rs.10/- to Rs.2/- on the effective date of the draft Scheme of Reduction of Capital.	
Page 2 @ para 5	As per the AGM held on 21.07.2021, 99.95% shareholders who attended have voted for the proposed reduction of capital and 3% voted against the scheme.	
Page 2 @ para 6	As per the Balance Sheets of the Petitioner Company for the years ended as at 31.01.2021, 31.03.2020, 31.03.2019 the Company has shown losses of (89,462,039), (800,63,554), (808,72,280) respectively.	
Page 3 @ para 7	The Applicant Company has furnished the information about the Accounting Treatment to be followed after the approval of the Reduction of capital and as per the Certificate dated 04.09.2021 from C. Ramachandram & Co., Chartered Accountants, which is submitted certifying that the proposed Accounting Treatment by the Company in Reduction of Share Capital is in conformity with Accounting Standards under Section 133 of Companies Act, 2013, and applied Rules.	
Page 3 @ para 8	The Company has furnished an affidavit dated 06.09.2021 with regard to the list of secured and unsecured creditor is true and correct.	

Olal

New

29

Date of Order: 06.01.2023

Vien

	Page 3 @ para 9	The Company has furnished letter stating that the Company has not accepted any deposits from the public and hence there are no arrears of repayment of the deposits or the interest thereon.			
	Page 3 @ para 10	The Company has related party transactions during the last two years. Hence, the Petitioner Company be advise to furnish the undertaking before the Hon'ble NCLT to the effect that they have complied with the provisions of Section 188 of the Companies Act, 2013.	the the the l part	Company has c provisions of Se Companies Act, ast 2 years and a y transactions as m's length.	ection 188 of 2013 during all the related
	Page 3 @ para 11	The proposal is for reduction of capital by Rs.2,05,01,600/- divided into 1,02,50,800 Equity Shares of Rs.2/ - each fully paid- up by reducing face value of each equity share from Rs.10/- to Rs.2/- of the total accumulated losses of Rs.819.72 Lakhs against			
and a second	Page 4 @ para 12	reduction in share capital. The face value of share is reduced from Rs.10/- to Rs.2/- duly adjusting against the accumulated losses and no pay out is made to the shareholders of the Company			
rabe	Para 4 @	As per the Secretarial Report of Company u/s 204 of the Companies Act, 2013, it is observed that there were certain non-compliances observed by BSE Limited with regard to the SEBI (LODR) Regulations, 2015 and imposed penalty. Hence, Petitioner Company may be directed to furnish	Comp 2020	observations tarial Audit Re pany for the Fir -21 and compli- e same is as foll Non- compliances Delay in submission (7 days) of Annual Report under Regulation 34 of	ance status

30

Date of Order: 06.01.2023

	compliance of the observations made in the Secretariat Audit Report and furnish an undertaking with regard to the compliance of		SEBI LODR Regulations.	through NEFT on 18.08.2021 vide UTR No.AXIC2123 04557383.
	the same before the Hon'ble NCLT. Further, BSE Limited has granted permission with regard to the present Scheme vide letter dated 08.06.2021 with some observations. In this regard, the Petitioner Company shall comply with the instructions/observations	2.	Delay in submission (1 day) of Shareholding Pattern under Regulation 31 of SEBI LODR Regulations.	Rs.1.1807+
	of BSE Limited.	3.	Delay in submission (1 day) of Corporate governance under Regulation 27 of SEBI LODR Regulations.	Complied. Paid an amount of Rs.8,260/- through NEFT on 18.08.2021 vide UTR No. AXIC212304 557383.
		4.	The Composition of Board of Directors is not as per Regulation 17 of SEBI LODR Regulations	Complied. Out of Six Directors, the Board contains One Women director and Three Independent Directors.
Land and a state of the state o		105	Delay in submission (85 days) of Related Party Transactions under Regulation 23(9) of SEBI LODR Regulations	Complied. Paid an amount of Rs.3,45,600/ - on 24,02,2021 through RTGS vide UTR No. UTIB520210 2240064456 5 and Rs.1,05,000/ - through NEFT vide UTR No.AXSK210 960005714.
		has	ubmitted that th complied with vations made	all the

new

Date of Order: 06.01.2023

		Secretarial Audit Report and further the Company has paid the penalty to BSE Limited as mentioned above.
Page 4 @ para 14	The Petitioner Company has shown a revenue of Rs.1,03,19,225/- during the year 2021 and Rs.1,94,33,088/- during the year 2020. However, on examination of the balance sheet of the company, it has shown a sum of Rs.50,55,000/- and Rs.41,61,460/- by way of sale to related parties. Except these two transactions, no major business was carried out by the company and the stock in trade during the financial year 2020-21 is Nil. The situation appears to be similar with that of previous years. Hence, detailed jurisdiction in this regard be furnished by the Petitioner company before the Hon'ble NCLT.	The Applicant company is submitted that the total revenue



Jour

VI. Heard submissions made by the Learned Counsel for the Applicant Company. It is pertinent to note here that according to Section 66 of the Companies Act, 2013, a Company having share capital may by a Special Resolution reduce the share capital in any manner and may extinguish or reduce its liability on any shares. It has been held in the case of **Reckitt Benckiser (India) Limited (2005) 122 DLT 612** that the question of reduction of share capital is a domestic concern of the Company and if the same is approved by majority of shareholders, court will confirm it, except in situation like unfair or inequitable transaction or objection by creditors.

ORDER



Considering the entire facts and circumstances of the case, reports filed by Bombay Stock Exchange and RD, Hyderabad and in response the reply filed by the Applicant Company and on perusal of the documents produced on record, the reduction of share capital appears to be fair and reasonable and is not contrary to public policy and does not violate any of the provisions of law. All the statutory compliances have been made under Section 66 of the Companies Act, 2013. There have been no objections from any

creditors. Hence, we hereby allow the Company Application with the following directions:-

- The Applicant Company to publish notices about registration of order and form of minutes of reduction of share capital by concerned Registrar of Companies in the same newspaper in which notices of the Application were published, within 14 days of registration.
- That a certified copy of this order including the minutes approved is to be delivered to the Registrar of Companies within 30 days of the receipt of the order.
- All concerned Regulatory Authorities to act on the certified copy of the order duly certified by the Registrar of National Company Law Tribunal.
- 4. This order should not be construed to convey the compliance of any laws or regulations, in case further approval or permission is required from any other regulatory authority or Government under the relevant laws or regulations.



5. This order should not be construed as regularizing or validating any irregularities, contravention of or other lapses if any under the provisions of any other laws including tax laws/regulations including FEMA.

VIII. Accordingly, CP 52/66/HDB/2021 is allowed and stands disposed of.

CHARAN SINGH MEMBER (TECHNICAL)

Surpany Law

Prabad Ban

Syamala

JUSTICE TELAPROLU RAJANI MEMBER (JUDICIAL)

ty Registrar / Assistant Registrar / Court Officer wational Company Law Tribunal, Hyderabad Bench प्रमाणित प्रति CERTIFIED TRUE COPY केन संख्या CASE NUMBER (A. SQ.)66(HDB) 2021 निर्णय का नार्गना DATE DF JUDGEMENT 6(1) 2025 प्रति तैयार किया गांव नार्ग्नेष्ठ प्रति तैयार किया गांव नार्ग्नेष्ठ COPY MADE READY ON 1611 (2025